Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients

被引:242
作者
Bastion, Y
Sebban, C
Berger, F
Felman, P
Salles, G
Dumontet, C
Bryon, PA
Coiffier, B
机构
[1] CTR HOSP LYON SUD, SERV HEMATOL, F-69495 PIERRE BENITE, FRANCE
[2] CTR HOSP LYON SUD, HEMATOL LAB, F-69495 PIERRE BENITE, FRANCE
[3] HOP EDOUARD HERRIOT, SERV HEMATOL, LYON, FRANCE
[4] HOP EDOUARD HERRIOT, PATHOL SERV, LYON, FRANCE
[5] HOP EDOUARD HERRIOT, HEMATOL LAB, LYON, FRANCE
关键词
NON-HODGKINS-LYMPHOMAS; BONE-MARROW TRANSPLANTATION; LARGE-CELL LYMPHOMA; LOW-GRADE; PROGNOSTIC FACTORS; HISTOLOGIC TRANSFORMATION; CLINICAL-FEATURES; TUMOR PROGRESSION; NATURAL-HISTORY; SURVIVAL;
D O I
10.1200/JCO.1997.15.4.1587
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To assess the incidence of lymphoma transformation in the natural history of follicular lymphoma (FL) patients and the factors that are predictive of this event. Patients and Methods: Two hundred twenty patients with FL treated in our institution between 1975 and 1990, with alpha median follow-up duration of 9 years, were included in this retrospective analysis. Results: Transformation was proven by histology in 34 patients or by cytology in 13 patients and was considered as highly probable on clinical arguments in five patients for an overall incidence of 24%. The probability of transformation was 22% at 5 years and 31% at 10 years and tended to plateau after 6 years. Predictive factors for transformation were nonachievement of complete remission (CR) after initial therapy (P < 10(-4)), low serum albumin level (< 35 g/L) (P = .001), and beta(2)-microglobulin level greater than 3 mg/L (P = .02) at diagnosis. In a multiparametric analysis, only beta(2)-microglobulin level retained prognostic significance for freedom-from-transformation (FFT) survival (P = .04). Transformation accounted for 44% of deaths and was associated with a poor outcome, with alpha median survival time of 7 months. Conclusion: Transformation is on early event in the course of the disease and is mainly observed in patients with known adverse prognostic factors or those who do not achieve CR after initial treatment. These findings may be useful to select follicular lymphoma patients for intensive therapeutic approaches. (C) 1997 by American Society of Clinical Oncology.
引用
收藏
页码:1587 / 1594
页数:8
相关论文
共 40 条
[1]   HISTOLOGIC CONVERSION IN THE NON-HODGKINS LYMPHOMAS [J].
ACKER, B ;
HOPPE, RT ;
COLBY, TV ;
COX, RS ;
KAPLAN, HS ;
ROSENBERG, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (01) :11-16
[2]   CLINICAL-FEATURES AND PROGNOSIS OF FOLLICULAR LARGE-CELL LYMPHOMA - A REPORT FROM THE NEBRASKA-LYMPHOMA-STUDY-GROUP [J].
ANDERSON, JR ;
VOSE, JM ;
BIERMAN, PJ ;
WEISENBURGER, DD ;
SANGER, WG ;
PIERSON, J ;
BAST, M ;
ARMITAGE, JO .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) :218-224
[3]  
ARMITAGE JO, 1981, CANCER TREAT REP, V65, P413
[4]   FOLLICULAR LARGE-CELL LYMPHOMA - INTERMEDIATE OR LOW-GRADE [J].
BARTLETT, NL ;
RIZEQ, M ;
DORFMAN, RF ;
HALPERN, J ;
HORNING, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (07) :1349-1357
[5]   FOLLICULAR LYMPHOAMS - ASSESSMENT OF PROGNOSTIC FACTORS IN 127 PATIENTS FOLLOWED FOR 10 YEARS [J].
BASTION, Y ;
BERGER, F ;
BRYON, PA ;
FELMAN, P ;
FFRENCH, M ;
COIFFIER, B .
ANNALS OF ONCOLOGY, 1991, 2 :123-129
[6]   INTENSIVE THERAPY WITH PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION IN 60 PATIENTS WITH POOR-PROGNOSIS FOLLICULAR LYMPHOMA [J].
BASTION, Y ;
BRICE, P ;
HAIOUN, C ;
SONET, A ;
SALLES, G ;
MAROLLEAU, JP ;
ESPINOUSE, D ;
REYES, F ;
GISSELBRECHT, C ;
COIFFIER, B .
BLOOD, 1995, 86 (08) :3257-3262
[7]  
BASTION Y, 1993, P AN M AM SOC CLIN, V12, P362
[8]  
COIFFIER B, 1993, SEMIN ONCOL, V20, P89
[9]   LNH-84 REGIMEN - A MULTICENTER STUDY OF INTENSIVE CHEMOTHERAPY IN 737 PATIENTS WITH AGGRESSIVE MALIGNANT-LYMPHOMA [J].
COIFFIER, B ;
GISSELBRECHT, C ;
HERBRECHT, R ;
TILLY, H ;
BOSLY, A ;
BROUSSE, N .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (08) :1018-1026
[10]  
Cox D.R., 2018, ANAL BINARY DATA